Stephan Moll, MD writes…
Apixaban (Eliquis) is one of the 3 new oral blood thinners. It is NOT approved at this point to prevent or treat DVT or PE (also referred to as venous thromboembolism or VTE). It is, however, FDA-approved for the use in patients with irregular heart beat (atrial fibrillation) to prevent stroke. As the studies on VTE have not been completed and as the drug is not FDA-approved for VTE, I would NOT use it off label in patients with VTE. However, for the health care professionals who prescribes apixaban for atrial fibrillation, we have made available the apixaban guideline (here) developed at our institution, the University of North Carolina (UNC) Health Care System.
Apixaban and VTE
In respect to venous thromboembolism, the disorder that Clot Connect mostly focuses on:
- Apixaban is not FDA-approved at this point for VTE prevention or treatment.
- The phase 3 clinical trial of apixaban in patients with acute DVT and PE is still ongoing (link here) and results are expected in the 2nd part of 2013.
- An apixaban secondary prevention trial (AMPLIFY-EXTENSION) was published in the N Engl J Med on Dec 8th, 2012, showing that apixaban, compared to placebo, decreased the risk of recurrent VTE without increasing the rate of major bleeding [ref 1].
- Agnelli G et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. Dec 8, 2012, pre-published on the web.
Support Forum: Questions or comments about the new oral blood thinners and its use? Go to the online Clot Connect Support Forum, category “Anticoagulant Use (Blood Thinners)”.
Disclosure: I have consulted for Janssen Pharmaceuticals, Boehringer-Ingelheim, and Daiichi.
Last updated: Feb 5th, 2013